Resistance to androgen-pathway drugs in prostate cancer

摘要

Antonarakis and colleagues (Sept. 11 issue) reported a significant association between the presence of androgen-receptor splice variant 7 messenger RNA (AR-V7) in circulating tumor cells and shorter prostate-specific antigen (PSA) progression-free survival, clinical or radiographic progression-free survival, and overall survival in men with metastatic castration-resistant prostate cancer who were treated with enzalutamide or abiraterone. Several treatment options (abiraterone, enzalutamide, sipu-leucel-T, and radium-223) have recently been shown to prolong survival in men with metastatic castration-resistant prostate cancer who have not previously been treated with chemotherapy; the identification of reliable biomarkers that can predict response should optimize treatment with these approaches.